We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Test Increases Specificity for Human Papillomavirus

By LabMedica International staff writers
Posted on 31 Mar 2011
Three different tests have been compared for the detection of human papillomavirus (HPV) on cervical specimens and correlated with the presence of cancer. More...


The tests are molecular diagnostic kits that either identify messenger ribonucleic acid (mRNA), or use hybrid capture DNA technology. A real-time multiplex nucleic acid sequence-based amplification assay (NASBA) for isothermal amplification and detection of mRNA was also compared.

Scientists from the Memorial University, (St. John's, NL, Canada), collaborating with others, tested cervical specimens from a random sample of 1,418 women referred for colposcopy and assessment of cervical cancer risk and 1,373 women undergoing routine screening. The three tests were the Aptima HPV assay which detects E6/E7 mRNA of 14 oncogenic types, a Hybrid Capture 2 DNA test (HC2), and an HPV Proofer assay which amplifies and detects E6/E7 mRNA from five high-risk oncogenic types. The oncogenes E6 and E7 are associated with HPV and these proteins are involved in initiation and mediation of oncogenic process that leads to cervical cancer, and to other HPV-associated cancers.

The investigators report that among 1,418 women studied, the Aptima HPV test, (Gen-Probe Inc.; San Diego, CA, USA), detected 96.3% of women with high-grade cervical intraepithelial neoplasia (CIN) or worse (CIN 2+) compared to 94.3% for the HC2, (Qiagen; Mississauga, ON, Canada). The Aptima test has far fewer false positives than HC2. Across histological grades, the Aptima assay showed significantly higher sensitivity and significantly lower specificity than the PreTect HPV-Proofer NASBA assay (Norchip; Klokkarstua, Norway), However, the Proofer test detected all eight cases of invasive cervical cancer, and this included the case which tested negative by HC2.

The authors concluded that their data indicated that the Aptima test is as sensitive as HC2, but more specific for detecting CIN 2+ and has the potential to serve as a reliable test for both primary cervical cancer screening and the triage of borderline cytological abnormalities. Samuel Ratnam, PhD, the senior author of the study, said, "Reducing false-positive result avoids unnecessary additional tests and follow-up, the associated health care costs, and distress to women. HPV infection is highly prevalent, but only a small fraction of the infected is at risk of developing HPV-associated cancers." The study was published in February 2011, in the Journal of Clinical Microbiology.

Memorial University
Gen-Probe Inc.
Qiagen
Norchip



Related Links:

New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more

Technology

view channel
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)

Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.